Amarin Announces Private Placement for up to $...(of similar meaning inconnection with any...),Health

Date:5/14/2008

of similar meaning in connection with any discussion of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: risks relating to the Company's ability to maintain its Nasdaq listing; Amarin's ability to maintain sufficient cash and other liquid resources to meet its operating and debt service requirements; the success of Amarin's research and development activities; decisions by regulatory authorities regarding whether and when to approve Amarin's drug applications, as well as their decisions regarding labeling and other matters that could affect the commercial potential of Amarin's products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be commercialized; competitive developments affecting Amarin's products under development; the effect of possible domestic and foreign legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin's ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates; governmental laws and regulations affecting Amarin's operations, including those affecting taxation; general changes in International generally accepted accounting principles; and growth in costs and expenses. A further list and description of these risks, uncertainties and other matters can be found in Amarin's Form 20-F for the fiscal year ended December 31, 2006, filed with the SEC on March 5, 2007, Amarin's statutory annual report for the year ended 31 December, 2006 furnished on a Form 6-K to the SEC on May 9, 2007, Amarin's Report of Foreign Issuer (Updated
'/>"/>

SOURCE Amarin Corporation Plc Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Amarin Regains Compliance With Nasdaq Listing Requirements
2. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
3. Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntingtons Disease Program
4. NightHawk Radiology Holdings, Inc. Announces Dutch Tender Offer for Its Common Stock
5. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
6. Veria Announces Acquisition of Massage Envy Ltd.
7. TOFUTTI Announces First Quarter Results
8. Natural Alternatives International, Inc. Announces Third Quarter Results
9. eDiets.com(R) Announces Q1 2008 Results
10. Boston Scientific Announces FDA Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
11. United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results